Research map: Estimating the budget impact of introducing dostarlimab as first line in treating endometrial cancer in Saudi Arabia

Back to the article

Papers in this map

  1. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions · Ming Yi · 2022 · 1517 citations · Cited by this paper
  2. Response to Kirshner et al.: updated cost consequence analyses using requested inputs · 2026 · Related
  3. Endometrial cancer · Emma J Crosbie · 2022 · 1383 citations · Cited by this paper
  4. Clinical burden and healthcare resource utilization after allogeneic hematopoietic stem cell transplant for sickle cell disease or β-thalassemia · 2026 · Related
  5. Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force · Sean D. Sullivan · 2013 · 1219 citations · Cited by this paper
  6. Cost-effectiveness of vagus nerve-mediated neuroimmune modulation for the treatment of moderate-to-severe rheumatoid arthritis · 2026 · Related
  7. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer · Vicky Makker · 2022 · 939 citations · Cited by this paper
  8. Interpreting per-death productivity estimates in human capital analyses of lung cancer: the role of working-age-restricted denominators · 2026 · Related
  9. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer · Mansoor Raza Mirza · 2023 · 870 citations · Cited by this paper
  10. An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma · 2026 · Related
  11. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer · Ramez Nassef Eskander · 2023 · 766 citations · Cited by this paper
  12. Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis · 2026 · Related
  13. Endometrial cancer · Vicky Makker · 2021 · 726 citations · Cited by this paper
  14. A system dynamics modelling protocol to evaluate the impact of a health financing mechanism for breast cancer pharmacotherapies in Malaysia · 2026 · Related
  15. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Ana Oaknin · 2022 · 674 citations · Cited by this paper
  16. The financial impact of surgical interventions for benign prostatic hyperplasia within a single NHS trust · 2026 · Related
  17. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial · Shannon Neville Westin · 2023 · 374 citations · Cited by this paper
  18. From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis · 2026 · Related
  19. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) · David Scott Miller · 2020 · 359 citations · Cited by this paper
  20. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019 · Baoxia Gu · 2021 · 344 citations · Cited by this paper
  21. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study · Ana Oaknin · 2022 · 342 citations · Cited by this paper
  22. Assessment of costs associated with adverse events in patients with cancer · William Bruce Wong · 2018 · 173 citations · Cited by this paper
  23. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer · Carol A Aghajanian · 2018 · 148 citations · Cited by this paper
  24. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors · Thierry André · 2023 · 138 citations · Cited by this paper
  25. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial · M.A. Powell · 2024 · 127 citations · Cited by this paper
  26. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study · Ana Oaknin · 2023 · 93 citations · Cited by this paper
  27. Recurrent Endometrial Cancer: Local and Systemic Treatment Options · Heidi Rütten · 2021 · 82 citations · Cited by this paper
  28. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial · Ramez Nassef Eskander · 2025 · 78 citations · Cited by this paper
  29. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial · Christian Marth · 2024 · 66 citations · Cited by this paper
  30. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma · Peter Graham Rose · 2017 · 34 citations · Cited by this paper
  31. Direct costs associated with adverse events of systemic therapies for advanced melanoma · Catherine Copley‐Merriman · 2018 · 27 citations · Cited by this paper
  32. Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer · Maojin You · 2023 · 16 citations · Cited by this paper
  33. Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer · Gengwei Huo · 2024 · 11 citations · Cited by this paper
  34. Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations · Quratulain Babar · 2023 · 10 citations · Cited by this paper
  35. Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis · Youwen Zhu · 2024 · 7 citations · Cited by this paper
  36. Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer · Shao-Jing Wang · 2025 · 5 citations · Cited by this paper
  37. Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective · Solomon James Lubinga · 2024 · 2 citations · Cited by this paper
  38. Elsisi G, Abdul Kareem H, Alaseiri A, et al. Costs of Adverse Event Management Associated with First-Line Cetuximab or Panitumumab in Metastatic Colorectal Cancer Patients in Saudi Arabia. · Gihan Hamdy Elsisi · 2025 · 1 citation · Cited by this paper
  39. Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis · Ziyad S. Almalki · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)